Lenograstim

Lenograstim
Clinical data
Trade names	Euprotin, Granocyte, Lenobio, Neutrogin
AHFS/Drugs.com	International Drug Names
ATC code	L03AA10 (WHO) ;
Identifiers
CAS Number	135968-09-1 ;
ChemSpider	none;
UNII	6WS4C399GB;
ECHA InfoCard	100.207.855
	(what is this?) (verify)

Lenograstim is a recombinant granulocyte colony-stimulating factor which functions as an immunostimulator.^[1]^[2] It is developed by Chugai Pharmaceuticals under the brand name Granocyte.

References

^ "USAN Council. List No. 340. New names. Lenograstim". Clin. Pharmacol. Ther. 52 (1): 112–113. July 1992. doi:10.1038/clpt.1992.117. PMID 1284891.
^ Amadori S, Suciu S, Jehn U, Stasi R, Thomas X, Marie JP, Muus P, Lefrère F, Berneman Z, Fillet G, Denzlinger C, Willemze R, Leoni P, Leone G, Casini M, Ricciuti F, Vignetti M, Beeldens F, Mandelli F, De Witte T (July 2005). "Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study". Blood. 106 (1): 27–34. doi:10.1182/blood-2004-09-3728. PMC 1895135. PMID 15761020.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.